Abstract
The positron emitting isotope 89Zr is an ideal radionuclide for use in positron emission tomography (PET) imaging with monoclonal antibodies (mAbs). This article reviews the cyclotron physics of 89Zr production, and the chemical separation methods for isolating it from yttrium target material. 89Zr coordination with the bifunctional chelate desferrioxamine B is discussed, along with the common procedures for attaching the chelate to mAbs. The review is intended to detail the procedure for creating 89Zr labeled mAbs, going from cyclotron to PET.
Keywords: 89Zr, zirconium-89, positron emission tomography, desferal, Immuno-PET, desferrioxamine, mAbs, monoclonal antibodies, cyclotron physics, yttrium target material, bifunctional chelate, desferrioxamine B
Medicinal Chemistry
Title: 89Zr Radiochemistry for Positron Emission Tomography
Volume: 7 Issue: 5
Author(s): Gregory W. Severin, Jonathan W. Engle, Todd E. Barnhart and R. Jerry Nickles
Affiliation:
Keywords: 89Zr, zirconium-89, positron emission tomography, desferal, Immuno-PET, desferrioxamine, mAbs, monoclonal antibodies, cyclotron physics, yttrium target material, bifunctional chelate, desferrioxamine B
Abstract: The positron emitting isotope 89Zr is an ideal radionuclide for use in positron emission tomography (PET) imaging with monoclonal antibodies (mAbs). This article reviews the cyclotron physics of 89Zr production, and the chemical separation methods for isolating it from yttrium target material. 89Zr coordination with the bifunctional chelate desferrioxamine B is discussed, along with the common procedures for attaching the chelate to mAbs. The review is intended to detail the procedure for creating 89Zr labeled mAbs, going from cyclotron to PET.
Export Options
About this article
Cite this article as:
W. Severin Gregory, W. Engle Jonathan, E. Barnhart Todd and Nickles R. Jerry, 89Zr Radiochemistry for Positron Emission Tomography, Medicinal Chemistry 2011; 7 (5) . https://dx.doi.org/10.2174/157340611796799186
DOI https://dx.doi.org/10.2174/157340611796799186 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Treatment with Radix Euphorbiae Ebracteolatae Significantly Decreases the Expression of E6 and L1, and Increases the Expression of p53 and Rb in HPV18-infected Human Foreskin Keratinocytes
Current Molecular Medicine Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Copper-62 Labeled ReCCMSH Peptide Analogs for Melanoma PET Imaging
Current Radiopharmaceuticals Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Eugenol Inhibits the Biological Activities of an Oral Squamous Cell Carcinoma Cell Line SCC9 <i>via</i> Targeting MIF
Anti-Cancer Agents in Medicinal Chemistry Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience